Aclarion (Aclarion) ROCE % : 0.00% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Aclarion ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Aclarion's annualized ROCE % for the quarter that ended in Dec. 2023 was 0.00%.

Aclarion ROCE % Historical Data

The historical data trend for Aclarion's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclarion ROCE % Chart

Aclarion Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-574.50

Aclarion Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial										-146.23	-282.18	-998.77	-	-

Aclarion ROCE % Calculation

Aclarion's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-4.303	/	( ( (2.915 - 0.689)	+	(2.46 - 3.188) )	/ 2 )
	=	-4.303	/	( (2.226	+	-0.728)	/ 2 )
	=	-4.303	/	0.749
	=	-574.50 %

Aclarion's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-3.488	/	( ( (1.543 - 2.371)	+	(2.46 - 3.188) )	/ 2 )
	=	-3.488	/	( ( -0.828	+	-0.728 )	/ 2 )
	=	-3.488	/	-0.778
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Aclarion (NAS:ACON) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Aclarion ROCE % Related Terms

Thank you for viewing the detailed overview of Aclarion's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aclarion (Aclarion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Aclarion Inc (NAS:ACON) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

8181 Arista Place, Suite 300, Broomfield, CO, USA, 80021

Website

http://www.aclarion.com

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

Executives

John Paul Lorbiecki	officer: Chief Financial Officer	238 CHEYENNE DRIVE, LAFAYETTE CO 80026
Brent Ness	director, officer: Chief Executive Officer	951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
Ryan Bond	officer: Chief Strategy Officer	951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
Stephen Deitsch	director	1600 BROADWAY, SUITE 700, DENVER CO 80202
William Wesemann	director	130 MONTALVO ROAD, REDWOOD CITY CA 94062
Jeffrey John Thramann	director, officer: Executive Chairman	8580 STRAWBERRY LANE, NIWOT CO 80503
Michael W Dirks	10 percent owner	811 EAST 30TH AVE, HUTCHINSON KS 67502
Nuvasive Inc	10 percent owner	7475 LUSK BLVD, SAN DIEGO CA 92121
Sc Capital 1 Llc	10 percent owner	1 COMPOUND DRIVE, HUTCHINSON KS 67502
Scott Breidbart	director	951 MARINERS ISLAND BLVD, SUITE 300, SAN MATEO CA 94404
Amanda Mae Sequira	director	951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
David K Neal	director	C/O ACLARION, INC., 951 MARINERS ISLAND BLVD, SUITE 300, SAN MATEO CA 94404